BACKGROUND: We explored the association between antituberculosis drug pharmacokinetics and treatment outcomes among patients with pulmonary tuberculosis in Botswana. METHODS: Consenting outpatients with tuberculosis had blood samples collected 1, 2, and 6 h after simultaneous isoniazid, rifampin, ethambutol, and pyrazinamide ingestion. Maximum serum concentrations (C(max)) and areas under the serum concentration time curve were determined. Clinical status was monitored throughout treatment. RESULTS: Of the 225 participants, 36 (16%) experienced poor treatment outcome (treatment failure or death); 155 (69%) were infected with human immunodeficiency virus (HIV). Compared with published standards, low isoniazid C(max) occurred in 84 patients (37%), low rifampin C(max) in 188 (84%), low ethambutol C(max) in 87 (39%), and low pyrazinamide C(max) in 11 (5%). Median rifampin and pyrazinamide levels differed significantly by HIV status and CD4 cell count category. Only pyrazinamide pharmacokinetics were significantly associated with treatment outcome; low pyrazinamide C(max) was associated with a higher risk of documented poor treatment outcome, compared with normal C(max) (50% vs. 16%; P < .01). HIV-infected patients with a CD4 cell count <200 cells/microL had a higher risk of poor treatment outcome (27%) than did HIV-uninfected patients (11%) or HIV-infected patients with a CD4 cell count 200 cells/microL (12%; P = .01). After adjustment for HIV infection and CD4 cell count, patients with low pyrazinamide C(max) were 3 times more likely than patients with normal pyrazinamide C(max) to have poor outcomes (adjusted risk ratio, 3.38; 95% confidence interval, 1.84-6.22). CONCLUSIONS: Lower than expected antituberculosis drug C(max) occurred frequently, and low pyrazinamide C(max) was associated with poor treatment outcome. Exploring the global prevalence and significance of these findings may suggest modifications in treatment regimens that could improve tuberculosis cure rates.
BACKGROUND: We explored the association between antituberculosis drug pharmacokinetics and treatment outcomes among patients with pulmonary tuberculosis in Botswana. METHODS: Consenting outpatients with tuberculosis had blood samples collected 1, 2, and 6 h after simultaneous isoniazid, rifampin, ethambutol, and pyrazinamide ingestion. Maximum serum concentrations (C(max)) and areas under the serum concentration time curve were determined. Clinical status was monitored throughout treatment. RESULTS: Of the 225 participants, 36 (16%) experienced poor treatment outcome (treatment failure or death); 155 (69%) were infected with human immunodeficiency virus (HIV). Compared with published standards, low isoniazid C(max) occurred in 84 patients (37%), low rifampin C(max) in 188 (84%), low ethambutol C(max) in 87 (39%), and low pyrazinamide C(max) in 11 (5%). Median rifampin and pyrazinamide levels differed significantly by HIV status and CD4 cell count category. Only pyrazinamide pharmacokinetics were significantly associated with treatment outcome; low pyrazinamide C(max) was associated with a higher risk of documented poor treatment outcome, compared with normal C(max) (50% vs. 16%; P < .01). HIV-infectedpatients with a CD4 cell count <200 cells/microL had a higher risk of poor treatment outcome (27%) than did HIV-uninfectedpatients (11%) or HIV-infectedpatients with a CD4 cell count 200 cells/microL (12%; P = .01). After adjustment for HIV infection and CD4 cell count, patients with low pyrazinamide C(max) were 3 times more likely than patients with normal pyrazinamide C(max) to have poor outcomes (adjusted risk ratio, 3.38; 95% confidence interval, 1.84-6.22). CONCLUSIONS: Lower than expected antituberculosis drug C(max) occurred frequently, and low pyrazinamide C(max) was associated with poor treatment outcome. Exploring the global prevalence and significance of these findings may suggest modifications in treatment regimens that could improve tuberculosis cure rates.
Authors: G Pillai; P B Fourie; N Padayatchi; P C Onyebujoh; H McIlleron; P J Smith; G Gabriels Journal: Int J Tuberc Lung Dis Date: 1999-11 Impact factor: 2.373
Authors: Marc Weiner; William Burman; Andrew Vernon; Debra Benator; Charles A Peloquin; Awal Khan; Stephen Weis; Barbara King; Nina Shah; Thomas Hodge Journal: Am J Respir Crit Care Med Date: 2003-01-16 Impact factor: 21.405
Authors: Justin J Wilkins; Grant Langdon; Helen McIlleron; Goonaseelan Colin Pillai; Peter J Smith; Ulrika S H Simonsson Journal: Eur J Clin Pharmacol Date: 2006-05-10 Impact factor: 2.953
Authors: Elizabeth A Talbot; Deborah C Hay Burgess; Nicholas M Hone; Michael F Iademarco; Michael J Mwasekaga; Howard J Moffat; Themba L Moeti; Ruth A Mwansa; Pinkie Letsatsi; Nandan T Gokhale; Thomas A Kenyon; Charles D Wells Journal: Clin Infect Dis Date: 2004-06-14 Impact factor: 9.079
Authors: Elizabeth L Corbett; Catherine J Watt; Neff Walker; Dermot Maher; Brian G Williams; Mario C Raviglione; Christopher Dye Journal: Arch Intern Med Date: 2003-05-12
Authors: Prema Gurumurthy; Geetha Ramachandran; A K Hemanth Kumar; S Rajasekaran; C Padmapriyadarsini; Soumya Swaminathan; P Venkatesan; L Sekar; S Kumar; O R Krishnarajasekhar; P Paramesh Journal: Clin Infect Dis Date: 2003-12-19 Impact factor: 9.079
Authors: Scott K Heysell; Charles Mtabho; Stellah Mpagama; Solomon Mwaigwisya; Suporn Pholwat; Norah Ndusilo; Jean Gratz; Rob E Aarnoutse; Gibson S Kibiki; Eric R Houpt Journal: Antimicrob Agents Chemother Date: 2011-10-03 Impact factor: 5.191
Authors: Museveni Justine; Anita Yeconia; Ingi Nicodemu; Domitila Augustino; Jean Gratz; Estomih Mduma; Scott K Heysell; Sokoine Kivuyo; Sayoki Mfinanga; Charles A Peloquin; Theodore Zagurski; Gibson S Kibiki; Blandina Mmbaga; Eric R Houpt; Tania A Thomas Journal: J Pediatric Infect Dis Soc Date: 2020-02-28 Impact factor: 3.164
Authors: Stellah G Mpagama; Norah Ndusilo; Suzanne Stroup; Happiness Kumburu; Charles A Peloquin; Jean Gratz; Eric R Houpt; Gibson S Kibiki; Scott K Heysell Journal: Antimicrob Agents Chemother Date: 2013-11-18 Impact factor: 5.191
Authors: Geetha Ramachandran; A K Hemanth Kumar; P K Bhavani; T Kannan; S Ramesh Kumar; N Poorana Gangadevi; V V Banurekha; L Sekar; N Ravichandran; G Mathevan; G N Sanjeeva; Rajeshwar Dayal; Soumya Swaminathan Journal: Antimicrob Agents Chemother Date: 2014-12-08 Impact factor: 5.191